Key facts
- Snipe Medical’s last known valuation is $3.7M (Sep 2024).
- It has raised $1.8M; the latest was Early Stage VC ($500K) in Feb 2026.
- Notable investors include Peregrine Ventures, Incentive Incubator, SHAAR.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Snipe Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Snipe Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Snipe Medical
Developer of a healthcare device designed to develop a novel cure to treat lung cancer. The company's device helps optimize cancer treatment with enhanced electrode positioning, while the non-thermal IRE modality enables streamlined, secure ablation of tumors occurring in previously challenging locations, enabling physicians at the frontline of cancer treatment with our IRE (Irreversible Electroporation) endoscopic ablation catheter system.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2021
- Employees
- 10
- Website
- snipemedical.com/
- Ownership
- Privately Held (backing)
Snipe Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Snipe Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Snipe Medical in its N-PORT filings yet. We sweep new filings monthly.